# Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

Source: https://onco.cc/key-papers/paper-cleopatra-n-engl-j-med-2012/  
OnCo record `paper-cleopatra-n-engl-j-med-2012` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the CLEOPATRA trial registered as NCT00567190, in New England Journal of Medicine (2012), chosen as the most cited paper whose own text cites the registry id.

## Summary

Background: The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer.

Methods: We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety.

Results: The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group.

Conclusions: The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).

Indexed on Europe PMC as PubMed record 22149875 (DOI 10.1056/nejmoa1113216). Its abstract cites the registry id NCT00567190, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: New England Journal of Medicine
- Year: 2012
- DOI: 10.1056/nejmoa1113216
- Authors: Baselga J, Cortés J, Kim SB, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT00567190 with the most citations, so it is the natural first reading for anyone following the CLEOPATRA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- N Engl J Med 2012: https://doi.org/10.1056/nejmoa1113216
- PubMed: https://pubmed.ncbi.nlm.nih.gov/22149875/
- Europe PMC: https://europepmc.org/article/MED/22149875
- ClinicalTrials.gov NCT00567190: https://clinicaltrials.gov/study/NCT00567190

## Connected records

- trials: [CLEOPATRA](https://onco.cc/trials/cleopatra/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)

---
JSON: https://onco.cc/api/v1/entities/paper-cleopatra-n-engl-j-med-2012.json